| 1 | AGA Clinical Practice Update on Surveillance for Hepatobiliary Cancers in Patients With Primary Sclerosing Cholangitis: Expert Review. Bowlus CL · 2019 · Clin Gastroenterol Hepatol | | +0.550 77 cites |
| 2 | Predicting Outcomes in Pediatric Ulcerative Colitis for Management Optimization: Systematic Review and Consensus Statements From the Pediatric Inflammatory Bowel Disease-Ahead Program. Orlanski-Meyer E · 2021 · Gastroenterology | | +0.218 47 cites |
| 3 | Effects of Primary Sclerosing Cholangitis on Risks of Cancer and Death in People With Inflammatory Bowel Disease, Based on Sex, Race, and Age. Trivedi PJ · 2020 · Gastroenterology | | +0.198 146 cites |
| 4 | Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Olsson R · 1991 · Gastroenterology | | +0.175 311 cites |
| 5 | Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Vera A · 2002 · Lancet | | +0.156 163 cites |
| 6 | Effects of orthotopic liver transplantation and immunosuppression on inflammatory bowel disease in primary sclerosing cholangitis patients. Stephens J · 1993 · Transplant Proc | | +0.115 49 cites |
| 7 | Sclerosing cholangitis after continuous hepatic artery infusion of FUDR. Kemeny MM · 1985 · Ann Surg | | +0.103 135 cites |
| 8 | Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Chapman RW · 1980 · Gut | | +0.102 739 cites |
| 9 | Lymphoplasmacytic sclerosing pancreatitis with cholangitis: a variant of primary sclerosing cholangitis extensively involving pancreas. Kawaguchi K · 1991 · Hum Pathol | | +0.089 466 cites |
| 10 | Vedolizumab in Inflammatory Bowel Disease Associated with Autoimmune Liver Disease Pre- and Postliver Transplantation: A Case Series. Lim TY · 2016 · Inflamm Bowel Dis | | +0.057 25 cites |
| 11 | Cholangiographic evaluation of bile duct carcinoma. Nichols DA · 1983 · AJR Am J Roentgenol | | +0.046 69 cites |
| 12 | Secondary sclerosing cholangitis: a comparison to primary sclerosing cholangitis. Gossard AA · 2005 · Am J Gastroenterol | | +0.039 78 cites |
| 13 | Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Mendes FD · 2007 · Am J Gastroenterol | | +0.031 102 cites |
| 14 | Extraintestinal manifestations of inflammatory bowel disease. Levine JS · 2011 · Gastroenterol Hepatol (N Y) | | +0.027 338 cites |
| 15 | The epidemiology and the pathogenesis of inflammatory bowel disease. Karlinger K · 2000 · Eur J Radiol | | +0.024 201 cites |
| 16 | Low-dose weekly methotrexate for unusual neutrophilic vascular reactions: cutaneous polyarteritis nodosa and Behçet's disease. Jorizzo JL · 1991 · J Am Acad Dermatol | | +0.023 74 cites |
| 17 | The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Bernstein CN · 2001 · Am J Gastroenterol | | +0.022 565 cites |
| 18 | Risk factors for biliary tract carcinogenesis. Chapman RW · 1999 · Ann Oncol | | +0.021 169 cites |
| 19 | Idiopathic adulthood ductopenia. A cause of chronic cholestatic liver disease and biliary cirrhosis. Ludwig J · 1988 · J Hepatol | | +0.018 147 cites |
| 20 | Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Rutter M · 2004 · Gastroenterology | | +0.018 973 cites |
| 21 | Primary sclerosing cholangitis. A study of forty-two cases. Warren KW · 1966 · Am J Surg | | +0.016 251 cites |
| 22 | Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management. Rogler G · 2021 · Gastroenterology | | +0.015 643 cites |
| 23 | The association of autoimmune disorders with inflammatory bowel disease. Snook JA · 1989 · Q J Med | | +0.014 175 cites |
| 24 | Azithromycin may reduce cholestasis in primary sclerosing cholangitis: a case report and serendipitous observation. Boner AL · 2007 · Int J Immunopathol Pharmacol | | +0.012 26 cites |
| 25 | Diffuse lymphoplasmacytic acalculous cholecystitis: a distinctive form of chronic cholecystitis associated with primary sclerosing cholangitis. Jessurun J · 1998 · Hum Pathol | | +0.012 24 cites |
| 26 | Plasma antioxidant levels in chronic cholestatic liver diseases. Floreani A · 2000 · Aliment Pharmacol Ther | | +0.010 53 cites |
| 27 | Oral vancomycin: treatment of primary sclerosing cholangitis in children with inflammatory bowel disease. Cox KL · 1998 · J Pediatr Gastroenterol Nutr | | +0.009 52 cites |
| 28 | SCLEROSING CHOLANGITIS. ASSOCIATION WITH REGIONAL ENTERITIS. ATKINSON AJ · 1964 · JAMA | | +0.009 57 cites |
| 29 | Gut-liver immunity. Trivedi PJ · 2016 · J Hepatol | | +0.009 72 cites |
| 30 | Ulcerative colitis disease activity as subjectively assessed by patient-completed questionnaires following orthotopic liver transplantation for sclerosing cholangitis. Gavaler JS · 1991 · Dig Dis Sci | | +0.009 59 cites |
| 31 | Validity of administrative data for the diagnosis of primary sclerosing cholangitis: a population-based study. Molodecky NA · 2011 · Liver Int | | +0.008 25 cites |
| 32 | Primary sclerosing cholangitis in childhood. el-Shabrawi M · 1987 · Gastroenterology | | +0.008 129 cites |
| 33 | Immunological similarities between primary sclerosing cholangitis and chronic sclerosing sialadenitis: report of the overlapping of these two autoimmune diseases. Tsuneyama K · 2000 · Dig Dis Sci | | +0.008 27 cites |
| 34 | Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis. Kim ER · 2014 · World J Gastroenterol | | +0.007 309 cites |
| 35 | Primary sclerosing cholangitis associated with systemic sclerosis. Fraile G · 1991 · Postgrad Med J | | +0.007 26 cites |
| 36 | Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Triantafillidis JK · 2009 · Anticancer Res | | +0.007 316 cites |
| 37 | Association of UCP2 -866 G/A polymorphism with chronic inflammatory diseases. Yu X · 2009 · Genes Immun | | +0.006 78 cites |
| 38 | Development of colon cancer after liver transplantation for primary sclerosing cholangitis associated with ulcerative colitis. Higashi H · 1990 · Hepatology | | +0.006 114 cites |
| 39 | Pancreatic cancer: epidemiology and risk factors. Krejs GJ · 2010 · Dig Dis | | +0.005 94 cites |
| 40 | Frequency of extraintestinal manifestations in patients with inflammatory bowel disease in Northwest Greece and review of the literature. Christodoulou DK · 2002 · Dig Liver Dis | | +0.005 51 cites |
| 41 | Improving outpatient services: the Southampton IBD virtual clinic. Hunter J · 2012 · Postgrad Med J | | +0.005 29 cites |
| 42 | Posttransplantation de novo tumors in liver allograft recipients. Penn I · 1996 · Liver Transpl Surg | | +0.005 90 cites |
| 43 | A case series of transplant recipients who despite immunosuppression developed inflammatory bowel disease. Riley TR · 1997 · Am J Gastroenterol | | +0.005 100 cites |
| 44 | Extraintestinal manifestations of inflammatory bowel disease. Bernstein CN · 2001 · Curr Gastroenterol Rep | | +0.005 29 cites |
| 45 | Immunohistochemical analysis of inflammation in primary sclerosing cholangitis. Ponsioen CY · 1999 · Eur J Gastroenterol Hepatol | | +0.005 51 cites |
| 46 | Diagnosis and classification of ulcerative colitis. Conrad K · 2014 · Autoimmun Rev | | +0.005 255 cites |
| 47 | Cancer risk in cystic fibrosis: a 20-year nationwide study from the United States. Maisonneuve P · 2013 · J Natl Cancer Inst | | +0.004 247 cites |
| 48 | Ulcerative colitis: analyses of 116 cases (do extraintestinal manifestations effect the time to catch remission?). Ozdil S · 2004 · Hepatogastroenterology | | +0.004 28 cites |
| 49 | Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. Lakatos PL · 2008 · World J Gastroenterol | | +0.004 344 cites |
| 50 | Chronic cholestatic diseases. Poupon R · 2000 · J Hepatol | | +0.004 133 cites |
| 51 | Inflammatory bowel disease as a risk factor for colorectal cancer. Lukas M · 2010 · Dig Dis | | +0.004 77 cites |
| 52 | Colorectal Cancer in Inflammatory Bowel Disease. Stidham RW · 2018 · Clin Colon Rectal Surg | | +0.003 227 cites |
| 53 | Sclerosing cholangitis in cystic fibrosis. Strandvik B · 1988 · Scand J Gastroenterol Suppl | | +0.003 39 cites |
| 54 | Is sclerosing cholangitis complicating ulcerative colitis a reversible condition? Wood RA · 1980 · Lancet | | +0.003 50 cites |
| 55 | ABC of colorectal cancer. Molecular basis for risk factors. Hardy RG · 2000 · BMJ | | +0.003 73 cites |
| 56 | Liver complications in inflammatory bowel diseases. Wieser V · 2013 · Dig Dis | | +0.003 25 cites |
| 57 | Simultaneous occurrence of primary sclerosing cholangitis and autoimmune chronic active hepatitis in a patient with ulcerative colitis. Rabinovitz M · 1992 · Dig Dis Sci | | +0.003 79 cites |
| 58 | Ulcerative colitis-associated colorectal cancer. Yashiro M · 2014 · World J Gastroenterol | | +0.003 217 cites |
| 59 | Hepatobiliary complications of ulcerative colitis. Lupinetti M · 1980 · Am J Surg | | +0.003 27 cites |
| 60 | Primary sclerosing cholangitis in Japan--analysis of 192 cases. Takikawa H · 1997 · J Gastroenterol | | +0.003 94 cites |
| 61 | Chronic inflammatory bowel disease and cancer. Pohl C · 2000 · Hepatogastroenterology | | +0.003 124 cites |
| 62 | Glomerulonephritis associated with inflammatory bowel disease. Report of a patient with chronic ulcerative colitis, sclerosing cholangitis, and acute glomerulonephritis. Wilcox GM · 1990 · Gastroenterology | | +0.003 48 cites |
| 63 | Carcinogenesis in inflammatory bowel disease. Herszenyi L · 2007 · Dig Dis | | +0.003 52 cites |
| 64 | Prevention of infection caused by immunosuppressive drugs in gastroenterology. Orlicka K · 2013 · Ther Adv Chronic Dis | | +0.002 66 cites |
| 65 | Diagnosis and management of cholangiocarcinomas: a comprehensive review. Yalcin S · 2004 · Hepatogastroenterology | | +0.002 30 cites |
| 66 | Aetiology and natural history of primary sclerosing cholangitis--a decade of progress? Chapman RW · 1991 · Gut | | +0.002 42 cites |
| 67 | Etiologic and clinical characteristics of peripheral and hilar cholangiocarcinoma. Altaee MY · 1991 · Cancer | | +0.002 91 cites |
| 68 | Anti-neutrophil cytoplasmic antibodies (ANCA): their detection and significance: report from workshops. Savige JA · 1994 · Pathology | | +0.002 27 cites |
| 69 | Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases. Muratori P · 2003 · Clin Exp Immunol | | +0.002 84 cites |
| 70 | Ulcerative colitis. Ghosh S · 2000 · BMJ | | +0.002 57 cites |
| 71 | Malignancies in inflammatory bowel disease: fact or fiction? van Hogezand RA · 2002 · Scand J Gastroenterol Suppl | | +0.002 39 cites |
| 72 | A survey of infectious agents as risk factors for primary sclerosing cholangitis: are Chlamydia species involved? Ponsioen CY · 2002 · Eur J Gastroenterol Hepatol | | +0.002 25 cites |
| 73 | Primary sclerosing cholangitis and disease distribution in inflammatory bowel disease. O'Toole A · 2012 · Clin Gastroenterol Hepatol | | +0.002 63 cites |
| 74 | Association of primary sclerosing cholangitis with HLA-B8. Chapman RW · 1983 · Gut | | +0.002 227 cites |
| 75 | Risk of primary sclerosing cholangitis is associated with nonsmoking behavior. van Erpecum KJ · 1996 · Gastroenterology | | +0.002 77 cites |
| 76 | Liver disorders in inflammatory bowel disease. Uko V · 2012 · Gastroenterol Res Pract | | +0.001 48 cites |
| 77 | Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts. Peyrin-Biroulet L · 2011 · Inflamm Bowel Dis | | +0.001 180 cites |
| 78 | Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis of 16 observational studies. Zheng HH · 2016 · Eur J Gastroenterol Hepatol | | +0.001 124 cites |
| 79 | Patient awareness of extraintestinal manifestations of inflammatory bowel disease. Huang V · 2013 · J Crohns Colitis | | +0.001 24 cites |
| 80 | The Impact of Inflammatory Bowel Disease in Canada 2018: Extra-intestinal Diseases in IBD. Bernstein CN · 2019 · J Can Assoc Gastroenterol | | +0.001 51 cites |
| 81 | Prevalence of penetrating disease and extraintestinal manifestations of Crohn's disease detected with CT enterography. Bruining DH · 2008 · Inflamm Bowel Dis | | +0.001 104 cites |
| 82 | Primary sclerosing cholangitis: diagnostic and management challenges. Sirpal S · 2017 · Clin Exp Gastroenterol | | +0.001 33 cites |
| 83 | Frequency and risk factors of low immunoglobulin levels in patients with inflammatory bowel disease. Rai T · 2015 · Gastroenterol Rep (Oxf) | | +0.001 36 cites |
| 84 | Comorbidities in adolescents with inflammatory bowel disease: findings from a population-based cohort study. Ghersin I · 2020 · Pediatr Res | | +0.001 20 cites |
| 85 | Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk? Dyson JK · 2012 · World J Gastroenterol | | +0.001 158 cites |
| 86 | Extraintestinal Manifestations of Inflammatory Bowel Disease. Vavricka SR · 2015 · Inflamm Bowel Dis | | +0.001 491 cites |
| 87 | Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Endo I · 2008 · Ann Surg | | +0.001 718 cites |
| 88 | Cholangitis: Diagnosis, Treatment and Prognosis. Mohammad Alizadeh AH · 2017 · J Clin Transl Hepatol | | +0.001 28 cites |
| 89 | Colon Cancer: Inflammation-Associated Cancer. Shawki S · 2018 · Surg Oncol Clin N Am | | +0.001 69 cites |
| 90 | Gut-liver axis. Zeuzem S · 2000 · Int J Colorectal Dis | | +0.001 91 cites |
| 91 | Colorectal cancer in patients with inflammatory bowel disease: the true impact of the risk. Herszényi L · 2015 · Dig Dis | | +0.001 58 cites |
| 92 | Immunopathogenesis of gastrointestinal and hepatobiliary diseases. Galperin C · 1997 · JAMA | | +0.001 24 cites |
| 93 | Gut dysbacteriosis and intestinal disease: mechanism and treatment. Meng X · 2020 · J Appl Microbiol | | +0.001 84 cites |
| 94 | The epidemiology of inflammatory bowel disease. Burisch J · 2015 · Scand J Gastroenterol | | +0.001 246 cites |
| 95 | Colorectal Cancer in Inflammatory Bowel Disease. Nebbia M · 2020 · Clin Colon Rectal Surg | | +0.001 37 cites |
| 96 | Extradigestive manifestations of IBD in pediatrics. Aloi M · 2009 · Eur Rev Med Pharmacol Sci | | +0.001 29 cites |
| 97 | Early onset of ulcerative colitis: long-term follow-up with special reference to colorectal cancer and primary sclerosing cholangitis. Lindberg J · 2008 · J Pediatr Gastroenterol Nutr | | +0.001 21 cites |
| 98 | Overview of molecular pathways in inflammatory bowel disease associated with colorectal cancer development. Azer SA · 2013 · Eur J Gastroenterol Hepatol | | +0.001 68 cites |
| 99 | Is colonoscopy alone sufficient to screen for ulcerative colitis-associated colorectal carcinoma? Bruewer M · 2003 · World J Surg | | +0.001 25 cites |
| 100 | Appropriate management of special situations in Crohn's disease (upper gastro-intestinal; extra-intestinal manifestations; drug safety during pregnancy and breastfeeding): Results of a multidisciplinary international expert panel-EPACT II. Mottet C · 2009 · J Crohns Colitis | | +0.000 26 cites |